Cabometyx (cabozantinib tablet)

P2, N=35, Active, not recruiting, Washington University School of Medicine | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Sep 2026

P2, N=101, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026

P2, N=30, Active, not recruiting, University of Arizona | Trial completion date: Jan 2026 --> Jan 2027

Collectively, c-MET is a core target in oncology, with rapidly evolving therapeutic agents and strategies. The development of innovative drugs and rational combinations will continue to refine c-MET-targeted therapy and expand treatment options for patients with c-MET-aberrant tumors.

Pralsetinib was added to osimertinib, resulting in a response lasting 4 months...After one month with alectinib only, osimertinib was added due to the progression, resulting in another response of more than two months. Upon progression with quadruple alterations (EGFR 19del, EGFR C797S, MET amplification, and RET fusions), cabozantinib-gefitinib combination was initiated, leading to rapid deterioration...At the same time, comprehensive genomic testing remains essential for therapeutic decision-making, with ctDNA analysis complementing tissue-based approaches. Notably, the FGFR3-TACC3 fusion may represent a novel resistance mechanism contributing to the limited efficacy of EGFR-TKI.

P2, N=10, Terminated, Ipsen | Trial completion date: Jun 2028 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Feb 2026; The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges

P2, N=48, Active, not recruiting, University of Colorado, Denver | Trial completion date: Feb 2026 --> Feb 2027

A high gene expression was observed in lenvatinib non-responder cell lines, and DepMap dose-response curves indicated modest responses to VEGF inhibitors. In vitro, ACHN was more sensitive to VEGF inhibition, particularly cabozantinib, whereas G6PDi-1 had stronger effects in 786-O, impairing viability, migration, and clonogenic capacity. Our findings support G6PD as a biomarker of tumor aggressiveness and G6PDi-1 as a potential therapeutic in RCC models.

Interestingly, A498-RAD10 cells were cross-resistant to cabozantinib, the tyrosine kinase inhibitor used in first-line treatment of mRCC with nivolumab...In silico data supported a context‑dependent role of PBRM1 in ccRCC patients. To the best of our knowledge, this is the first description of a mechanism of RAD001 and cabozantinib resistance through PBRM1 overexpression and CXCR7/CXCR4 downregulation and suggest new therapeutic perspective for cabozantinib-resistant patients.

P3, N=291, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Feb 2026 --> Nov 2027

Celiac disease developed in 3 patients after initiating biologic therapy: a 21-year-old female with psoriasis receiving ixekizumab (interleukin-17 antagonist) and risankizumab (interleukin-23 antagonist); a 49-year-old female with invasive ductal carcinoma of the breast after pertuzumab (human epidermal growth factor receptor 2 antagonist); and an 82-year-old male taking cabozantinib (multityrosine kinase inhibitor) for renal cell carcinoma. We have identified 3 cases of celiac disease that presented after initiating new immune-modulating medications. It is important to consider celiac disease and nonceliac villous atrophy in the differential for diarrhea developing during or after a new therapy as it heavily impacts management and may eliminate the need for alternate therapies that include steroid courses, cessation of therapy, or even gluten-free diet.

P3, N=450, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting